Primary Sclerosing Cholangitis
Watchlist
Retrieved
2022-04-26
Source
Trials
—
Genes
MST1,
ABCB4,
UBASH3A,
TCF4,
BCL2L11,
HIF1A,
GPR35,
NOS2,
IL2RA,
SH2B3,
ATXN2,
RMI2,
RBM45,
KIAA1109,
BSN,
PUS10,
MMEL1,
SIK2,
MIR4435-2HG,
HLA-DRB1,
RIC8B,
HDAC7,
CD226,
ACAD8,
PRKD2,
PHLDB1,
CFTR,
HLA-B,
GPBAR1,
FUT2
MST1,
ABCB4,
UBASH3A,
TCF4,
BCL2L11,
HIF1A,
GPR35,
NOS2,
IL2RA,
SH2B3,
ATXN2,
RMI2,
RBM45,
KIAA1109,
BSN,
PUS10,
MMEL1,
SIK2,
MIR4435-2HG,
HLA-DRB1,
RIC8B,
HDAC7,
CD226,
ACAD8,
PRKD2,
PHLDB1,
CFTR,
HLA-B,
GPBAR1,
FUT2,
MICA,
CCR5,
IL2,
TNF,
PSC,
HLA-DQA1,
MET,
IL10,
DLAT,
HLA-DRB3,
HLA-C,
NR1H4,
GP2,
CD28,
FBN2,
GGTLC1,
ALB,
NLRP3,
NOTCH1,
LOC102724197,
MMP3,
CDKN2A,
FGF19,
IFNG,
DEFB4B,
STS,
HLA-DQB1,
HP,
ICAM1,
TLR4,
TLR9,
ARSA,
TP53,
CXCL8,
FOXP3,
LOXL2,
PYCARD,
SLC17A5,
VDR,
IL6,
H3P10,
CEACAM5,
PTGS2,
NR1I2,
TNFSF10,
STAT4,
DEFB4A,
EGFR,
ETS1,
PNPLA3,
CD14,
MIR200B,
IL21,
HAMP,
HLA-A,
MAPK3,
GPT,
CASP3,
NOD1,
TNFRSF25,
PTGES,
TBC1D9,
HSPB3,
PDZD2,
NOL3,
ARID1A,
SOCS1,
XPR1,
GRAP2,
KLRK1,
DLG5,
MGLL,
KMT2B,
BTG3,
CCR9,
SLC9A3R1,
TXNIP,
ABCB11,
AHSA1,
AOC3,
CFLAR,
KRT20,
WWC1,
SARNP,
KIF12,
CTHRC1,
KCNH8,
DEFB104A,
HT,
CCBE1,
NANOS2,
MIR122,
MIR150,
MIR200C,
MIR21,
MIR222,
DEFB104B,
MIR483,
CCR2,
PBC2,
KLRC4-KLRK1,
GATD3B,
MTCO2P12,
RSPO3,
JAM3,
KCNH4,
AGBL2,
TXN2,
RNF19A,
POLDIP2,
B3GAT1,
CD274,
ICOS,
IL22,
CUZD1,
NEUROG3,
IL23A,
TM6SF2,
MADCAM1,
WDR11,
USE1,
RETN,
AICDA,
NOD2,
UBE2Z,
NEIL1,
GATD3A,
ABCA4,
AIMP2,
CX3CR1,
DDC,
DEFB1,
DNASE1,
SLC26A3,
ELK1,
ERBB2,
FBL,
F3,
PTK2B,
FOXO1,
FOXO3,
FUT3,
GABPA,
GCLC,
GCLM,
NR3C1,
GSTT1,
HCLS1,
HLA-DOA,
HLA-DPB1,
HLA-DRB5,
HES1,
IL1A,
DCT,
CTNNB1,
VIM,
CTLA4,
AGA,
JAG1,
AKT1,
ABCD1,
ANXA2,
AIRE,
AREG,
ADGRB3,
BCL2,
BCL2L1,
BCL3,
CFB,
C3,
MS4A1,
ENTPD1,
CD40LG,
CD47,
CD68,
CEACAM3,
CEACAM7,
CHRM3,
CRK,
MAPK14,
IL1B,
IL1RN,
IL12A,
IL13,
ABCB1,
PIK3CD,
POLR2G,
PPARA,
MAPK1,
PSG2,
AFP,
S100A8,
S100A12,
CCL20,
CCL21,
CCL25,
SDC1,
SLC10A2,
SOD2,
SPP1,
SPTBN1,
SRY,
SULT2A1,
TERC,
TFF3,
TXN,
TXNRD1,
PDZK1,
PAEP,
ORM2,
KMT2A,
IL15,
IL17A,
INSRR,
ISG20,
LGALS3BP,
LSS,
MCL1,
MEFV,
MEN1,
MICB,
MME,
DDR2,
MMP1,
MMP2,
MMP9,
MMP14,
MPO,
COX2,
NCAM1,
NFE2L2,
NOTCH3,
NRAS,
RLN2
Drugs
(S)-3-((S)-2-(2-((2,6-difluorophenyl)amino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid,
Cilofexor,
Maralixibat
(S)-3-((S)-2-(2-((2,6-difluorophenyl)amino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid,
Cilofexor,
Maralixibat,
Norursodeoxycholic acid,
Obeticholic acid
(
OCALIVA
),
Recombinant human monoclonal antibody binding to vascular adhesion protein-1,
Variant of recombinant human fibroblast growth factor 19
Registered!
Primary sclerosing cholangitis (PSC) is characterized by inflammation in the bile ducts (cholangitis) that leads to scarring (sclerosis), narrowing of the ducts, and a buildup of bile in the liver. Early signs and symptoms include extreme tiredness, abdominal pain, and itchiness. As the condition worsens it may cause jaundice, an enlarged spleen, and eventually liver cirrhosis and failure. Other complications may include weight loss, vitamin deficiency, and osteoporosis. Many people with PSC develop other autoimmune conditions such as inflammatory bowel disease, type 1 diabetes, celiac disease, or thyroid disease. PSC is also a risk factor for cancer of the bile ducts (cholangiocarcinoma).